Pharma wants more PhIII assets than biotech can supply, and more market data
This article was originally published in Scrip
Executive Summary
Biotechnology dealmakers confirmed the findings of a recent unsurprising survey result: pharmaceutical and mid-market biopharma companies that want to license or acquire biotech innovations are keenly focused on the later stage assets.